Contracting research by academic researchers is a specific manner of benefiting from academic research, knowledge and facilities. The Amsterdam research landscape offers a broad range of knowledge and expertise that can be mobilized. Think for instance of:
In contract research and contract manufacturing, you define together with the researcher what is to be expected in terms of output (data, materials, inventories, reports etc.) and standards (quality standards etc.). Together with our researchers you discuss which joined efforts are needed to deliver the required outcomes and to what fee the work will be performed.
At IXA we can take care of the legal arrangements of the cooperation and can draft the research contracts in which rights on intellectual property and ownership on application are described. Of course, these contracts will be tuned to the particular nature of the activities and the needs and interests of the parties involved.
MedTech startup Sirius Medical has received CE Mark approval for Sirius Pintuition, a non-radioactive device to localize breast tumors. In 2016 Bram Schermers, then a scientist at NKI, pitched an early concept at the annual Amsterdam Science & Innovation Awards and won first prize! His pitch also caught the attention of seasoned entrepreneur Hubert Martens, […]News
CimCure, a spin-off of Amsterdam UMC and focusing on cancer immunotherapies for solid tumors, signed a strategic partnership agreement for in-licensing CimCure’s iBoost technology with Intravacc, a worldwide leading translational research and development vaccine organization with an extensive track record in developing viral and bacterial vaccines. The iBoost (immune boost) technology was developed at Amsterdam […]News
An annual survey held by the program directors of the Joint Master Entrepreneurship (UvA/ VU), Bram Kuijken and Enno Masurel, has found that 17.8% of alumni have founded their own company and 11.0% are currently working freelance. Additionally, the study found that 41.9% of alumni is employed by a startup (19.7%) or a scale-up (22.2%). […]News